Supernus reported 18% sales growth and raised its 2026 sales and operating profit forecasts, with demand rising for several drugs. Its Indivior merger is still pending, so expected savings have not arrived.
That points to stronger demand for Supernus's medicines and a stronger base for future sales. The merger could add cost savings and cash generation, but it has not closed, so those gains are not yet in hand.
Indivior is expected to join a merger that could strengthen earnings and cash generation. The deal has not closed, so those benefits remain expected rather than delivered.
Follow Supernus Pharmaceuticals (SUPN) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for SUPN